Injectable Drug Delivery

The Essential Annual Conference for Pharmaceutical and Medical Device Professionals in the Parenteral Drug Delivery Industry (London, United Kingdom - March 22-23, 2018)

DUBLIN, Dec. 15, 2017 /PRNewswire/ --

The "Injectable Drug Delivery: The Essential Annual Conference for Pharmaceutical and Medical Device Professionals in the Parenteral Drug Delivery Industry" conference has been added to Research and Markets' offering.

Agenda:

Programme - Day one

Chairman's welcome and introduction

Dr Greg Berman, Independent Consultant, UK

Trends in Injection Devices

• Needs - the evolving patient, market, industry and regulatory expectations
• Approaches: responding with appropriate solutions
• Solutions: Some optimised, customised and novel technologies
• Pathways: Navigating designations and the changing framework
• Outcomes: Recent approvals, setbacks and regulator feedback

Mark Chipperfield, Company Director and Principal Consultant, Corvus Device, UK

Latest devices - connectivity with injectables

• Improved patient health and adherence through new technologies

Markus Bauss, Managing Director, SHL Group, Germany

Ypsomed delivery systems for large volume self-injection and connectivity

• Recent self-injection market trends with a focus on autoinjectors
• SmartPilot reusable add-ons and their integration into the connected ecosystem - YpsoDose patch injector: making life simpler for patients and pharma companies

Ian Thompson, Vice President Business Development, Ypsomed

Connected health - getting to market with an electronic auto-injector, app and cloud services

• Data
• Analytics
• Artificial intelligence

Neil Williams, Director, Front-End Innovation, Head of Connected Health, Medicom Innovation Partner, UK

Pre-filled syringes over time

• Evolution of processes and equipment
• Evolution of components
• Evolution of applications and application systems

Andreas Rothmund, Qualified Person, Vetter Pharma-Fertigung GmbH & Co KG Germany

Using polymeric PDC technology to improve auto-injector design

• Polymeric primary drug container (PDC) technology unlocks the design freedom constraints of existing PDC systems, providing the ability to fully address both the needs of the user and drug
• Increased design freedoms allow PDC components to be configured freely to resolve issues typically seen with glass-based systems
• An integrated approach to device design reduces the impact on the user, whilst ensuring all required user interface features are present without compromise